Tenon Medical back in Nasdaq bid-price compliance

Tenon Medical, Inc. (TNON) reports that on August 24, 2026 it received written notice from Nasdaq’s Listing Qualifications staff that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).

Rhea-AI Filing Summary

Tenon Medical, Inc. (TNON) reports that on August 24, 2026 it received written notice from Nasdaq’s Listing Qualifications staff that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). Nasdaq has confirmed that this compliance matter is now closed, meaning the company’s common stock and warrants continue to be listed on The Nasdaq Stock Market LLC.

Positive

• Nasdaq confirmed Tenon Medical has regained compliance with the minimum bid price requirement under Rule 5550(a)(2), and the related listing matter is now closed.

Negative

• None.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Filing Date: August 24, 2026 Par value per share: $0.001 per share Nasdaq Listing Rule: Rule 5550(a)(2)

3 metrics

Filing Date August 24, 2026 Date Nasdaq confirmed Tenon Medical regained compliance with the minimum bid price requirement

Par value per share $0.001 per share Par value of Tenon Medical common stock listed on Nasdaq

Nasdaq Listing Rule Rule 5550(a)(2) Minimum bid price requirement with which Tenon Medical has regained compliance

Key Terms

minimum bid price requirement, Nasdaq Listing Rule 5550(a)(2), Emerging Growth Company

3 terms

minimum bid price requirement market

"regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2)"

A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.

Nasdaq Listing Rule 5550(a)(2) regulatory

"compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2)"

Emerging Growth Company regulatory

"Emerging Growth Company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What Nasdaq update did Tenon Medical (TNON) announce on August 24, 2026?

Tenon Medical announced that on August 24, 2026, Nasdaq’s Listing Qualifications staff confirmed the company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), and that this compliance matter is now closed.

Is Tenon Medical (TNON) still listed on Nasdaq after this 8-K?

Yes. Nasdaq notified Tenon Medical that it has regained compliance with the minimum bid price requirement under Rule 5550(a)(2), and stated that the matter is now closed, so its common stock and warrants remain listed on The Nasdaq Stock Market LLC.

Which Nasdaq rule did Tenon Medical (TNON) regain compliance with?

Tenon Medical regained compliance with the Nasdaq Listing Rule 5550(a)(2), which sets the minimum bid price requirement for continued listing of its securities on The Nasdaq Stock Market LLC.

What securities of Tenon Medical (TNON) are listed on Nasdaq?

Tenon Medical lists its Common Stock, par value $0.001 per share, under the symbol TNON, and its warrants under the symbol TNONW on The Nasdaq Stock Market LLC.

Does the 8-K state that Tenon Medical (TNON) is an Emerging Growth Company?

Yes. The filing indicates that Tenon Medical is an Emerging Growth Company as defined under applicable rules, which affects certain reporting and regulatory requirements for the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/24/2026 - 01:24 PM EDT Accepted by SEC EDGAR 08/24/2026 - 01:23 PM EDT Learn about SEC filing dates

false 0001560293 0001560293 2026-08-24 2026-08-24 0001560293 tnon:CommonStockParValue0.001PerShareMember 2026-08-24 2026-08-24 0001560293 tnon:WarrantsMember 2026-08-24 2026-08-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported):

August 24, 2026

TENON MEDICAL, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-41364		45-5574718
(State or other jurisdiction		(Commission File Number)		(IRS Employer
of incorporation)				Identification No.)

104 Cooper Court
Los Gatos, CA		95032
(Address of principal executive offices)		(Zip Code)

(408) 649-5760

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		TNON		The Nasdaq Stock Market LLC
Warrants		TNONW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On August 24, 2026, Tenon Medical, Inc., a Delaware corporation (the “Company”), issued a press release (the “Press Release”) announcing that on August 24, 2026 the Company received written notification from the Listing Qualifications staff of The Nasdaq Stock Market LLC confirming that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), and this matter is now closed.

A copy of the Press Release referenced above is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “1934 Act”), nor shall it be deemed “incorporated by reference” into any filing under the Securities Act of 1933, as amended, or the 1934 Act, except as may be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

The following exhibits are being filed herewith:

Exhibit No.		Description
99.1		Press Release of Tenon Medical, Inc., dated August 24, 2026.
104		Cover Page Interactive Data File (embedded with the Inline XBRL document).

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 24, 2026	TENON MEDICAL, INC.
	(Registrant)
	By:	/s/ Steven M. Foster
	Name:	Steven M. Foster
	Title:	Chief Executive Officer and President

2

Filing Exhibits & Attachments

5 documents

Press Releases

• EX-99.1 PRESS RELEASE OF TENON MEDICAL, INC., DATED AUGUST 24, 2026 9.5 KB

Other Documents

• EX-101 XBRL SCHEMA FILE 3.6 KB
• EX-101 XBRL DEFINITION FILE 25.9 KB
• EX-101 XBRL LABEL FILE 35.6 KB
• EX-101 XBRL PRESENTATION FILE 24.6 KB